ICON plc
ICON plc is a global provider of clinical, consulting, and commercial services, dedicated to helping pharmaceutical, biotechnology, and medical device companies bring new drugs and devices to market faster. The company offers a comprehensive range of services that span the entire lifecycle of product development, from early clinical phases to post-marketing. ICON is committed to delivering high-quality, harmonized data and innovative solutions to improve patient recruitment, retention, and engagement, while ensuring regulatory compliance and operational efficiency.
Industries
Nr. of Employees
Very Large (1000+)
ICON plc
2100 Pennbrook Parkway, North Wales, PA 19454, USA
Products
AI system for forecasting post-marketing regulatory requirements
An AI-enabled predictive system that analyses regulatory databases and real-world drug data to forecast post-marketing study requirements and inform mitigation strategies.
AI-driven site identification and selection tools
Software-enabled tools that integrate and interrogate multiple data sources to support site feasibility and selection decisions using AI and predictive analytics.
AI system for forecasting post-marketing regulatory requirements
An AI-enabled predictive system that analyses regulatory databases and real-world drug data to forecast post-marketing study requirements and inform mitigation strategies.
AI-driven site identification and selection tools
Software-enabled tools that integrate and interrogate multiple data sources to support site feasibility and selection decisions using AI and predictive analytics.
Expertise Areas
- Clinical trial management (Phase I–IV)
- Real-world data and real-world evidence
- Database mapping and RWD feasibility assessment
- Clinical data management and biostatistics
Key Technologies
- AI and machine learning
- Real-world data integration
- Predictive analytics
- Radiomics and quantitative imaging analysis
News & Updates
Using exclusive data from ICON’s 2023 survey with Citeline, this report presents valuable insights from 133 influential decision-makers within biotech and venture capital organisations from across North America, Europe, and Asia Pacific.
This whitepaper describes the rigorous, iterative linguistic validation process for COAs that ensures conceptual equivalency and cultural relevance for each required translation.
This whitepaper discusses the transition from paper to electronic versions of documents in clinical research to improve participant experience and data quality.
This whitepaper details the prerequisites for controlled use of Clinical Outcome Assessments (COAs) and suggestions for streamlining the licensing process.
This whitepaper describes the adoption of an eCOA solution and shares a recommended approach to planning and implementing eCOA to mitigate risks of delaying study start-up.
This whitepaper suggests a design overhaul for scientific posters to make a lasting impression during poster sessions.
Using exclusive data from ICON’s 2023 survey with Citeline, this report presents valuable insights from 133 influential decision-makers within biotech and venture capital organisations from across North America, Europe, and Asia Pacific.
This whitepaper describes the rigorous, iterative linguistic validation process for COAs that ensures conceptual equivalency and cultural relevance for each required translation.
This whitepaper discusses the transition from paper to electronic versions of documents in clinical research to improve participant experience and data quality.
This whitepaper details the prerequisites for controlled use of Clinical Outcome Assessments (COAs) and suggestions for streamlining the licensing process.
This whitepaper describes the adoption of an eCOA solution and shares a recommended approach to planning and implementing eCOA to mitigate risks of delaying study start-up.
This whitepaper suggests a design overhaul for scientific posters to make a lasting impression during poster sessions.